Related Experiment Video
Updated: Aug 9, 2026
09:03
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
Current strategies for modulating lymphangiogenesis signalling pathways in human disease
S A Stacker1, R A Hughes, R A Williams
1Angiogenesis Laboratory, Ludwig Institute for Cancer Research, PO Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia. steven.stacker@ludwig.edu.au
Current Medicinal Chemistry
|April 14, 2006
Summary
Vascular endothelial growth factors (VEGFs) like VEGF-C and VEGF-D promote lymphatic vessel growth. Targeting these factors offers new therapeutic strategies for cancer metastasis and lymphedema.
Area of Science:
- Molecular Biology
- Cell Biology
- Medical Science
Background:
- Vascular endothelial growth factors (VEGFs) regulate lymphatic vessel growth (lymphangiogenesis).
- Dysregulated lymphatic vessel function is implicated in various human pathologies, including cancer and lymphedema.
Purpose of the Study:
- To explore the therapeutic potential of targeting VEGF-C and VEGF-D for treating diseases involving lymphatic vessels.
- To investigate the role of VEGF-C and VEGF-D in cancer metastasis and lymphedema.
Main Methods:
- Review of existing literature on VEGF family members, lymphangiogenesis, and related pathologies.
- Analysis of experimental studies demonstrating the effects of lymphangiogenic growth factors in tumor models.
Main Results:
- VEGF-C and VEGF-D induce lymphangiogenesis in vivo.
- Elevated VEGF-C and VEGF-D correlate with tumor metastasis and poor prognosis in various cancers.
- Lymphangiogenesis induced by these factors can facilitate tumor cell spread via lymphatics.
Conclusions:
- Targeting VEGF pathways presents a promising therapeutic avenue for conditions like lymphedema.
- Modulating lymphangiogenesis offers potential new treatments for cancer and other diseases.
- Further research into molecules controlling lymphangiogenesis can lead to novel drug development.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...